Tuesday - November 4, 2025
GSK Acquires Exclusive Rights From Syndivia for Antibody-Drug Conjugate in Prostate Cancer
October 28, 2025
LONDON, England, Oct. 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Oct. 27, 2025:

* * *

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

* Metastatic castration-resistant prostate cancer (mCRPC) remains a significant health burden for men with critical need for novel targeted treatments

* Agreement adds a new preclinical ADC with potential . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products